Doctor Belleville, a professor at Université Laval's School of Psychology arrived at these results through analysis of 12 years of data on over 14.000 Canadians in Statistics Canada's National Population Health Survey. The data includes information on the social demographics, lifestyle, and health of Canadians age 18 to 102, surveyed every two years between 1994 and 2007.
During this period, respondents who reported having used medication to treat insomnia or anxiety at least once in the month preceding the survey had a mortality rate of 15.7 per cent. Respondents who reported not having used such medications had a rate of 10.5 per cent. After controlling for personal factors that might affect mortality risk, notably alcohol and tobacco consumption, physical health, physical activity level, and the presence or absence of depressive symptoms among participants, Belleville established that the consumption of sleeping pills or anxiety-relieving medications was associated with a 36 per cent increase in the risk of death.
A number of hypotheses have been put forward to explain the link between use of these medications and increased mortality. Sleeping pills and anxiolytics affect reaction time, alertness, and coordination and are thus conducive to falls and other accidents. They may also have an inhibiting effect on the respiratory system, which could aggravate certain breathing problems during sleep. These medications are also central nervous system inhibitors that may affect judgment and thus increase the risk of suicide.
"These medications aren't candy, and taking them is far from harmless,"commented Belleville. "Given that cognitive behavioral therapies have shown good results in treating insomnia and anxiety, doctors should systematically discuss such therapies with their patients as an option. Combining a pharmacological approach in the short term with psychological treatment is a promising strategy for reducing anxiety and promoting
MEDICA.de; Source: Université Laval